A Wisconsin study links blood ImP with cognitive decline. Learn why the findings do not support a new diet or probiotic recommendation.
On June 26, 2026, researchers published a study in Nature Communications examining links between the gut-derived molecule imidazole propionate (ImP) and cognition in adults without cognitive impairment. The study combined observational human data with mouse and laboratory experiments. News coverage in October renewed attention to these findings.
In the original paper, researchers examined blood ImP levels in 1,196 adults without cognitive impairment. Participants came from Wisconsin research cohorts that included the Wisconsin Registry for Alzheimer’s Prevention.
The human analysis connected higher blood ImP with several findings:
These findings concern both cognitive performance and biological measurements. Lower test scores describe performance on cognitive assessments. Faster decline describes how performance changed over time. The blood-marker findings add another type of information to the study.
ScienceDaily quoted senior author Federico Rey saying that participants with the highest ImP levels “also experienced much faster cognitive decline.” That observation is the central human finding behind the report. It makes ImP a candidate for further research into the relationship between gut bacteria and brain aging.
ImP is a molecule produced by some gut bacteria while they use histidine. Histidine is an amino acid that the body needs and that occurs in many foods. The study examined this bacterial product in blood rather than treating all gut bacteria as a single category.
That distinction matters when reading microbiome headlines. The research question concerns a particular molecule and its links with cognitive measures. It is not simply a claim that having more or fewer gut bacteria determines brain health.
Rey also cautioned against judging a microbe's influence only by its abundance. Medical Daily quoted him saying that “a microbe doesn't have to be abundant to have an impact on the host.” His comment helps explain why researchers are interested in what bacteria produce rather than only how numerous they are.
The study also included experiments beyond the human observations. Researchers reported increased Alzheimer’s-related pathology in mice given ImP. Separate laboratory experiments examined effects on the protective barrier between the blood and brain.
ScienceDaily identified the paper as “Gut bacterial metabolite imidazole propionate potentiates Alzheimer’s disease pathology.” Its findings bring together measurements in people and experimental work intended to investigate possible biological explanations. Those parts of the paper answer different research questions and need to be read separately.
For readers thinking about everyday brain health, the immediate implication is modest: ImP is a research lead rather than a new dietary target. Medical Daily's coverage reports that this research has not shown a diet or probiotic that lowers ImP or protects memory.
That leaves no evidence-based ImP food plan to adopt from this study. It also leaves no basis here for choosing a supplement specifically to reduce the molecule. A claim about an ImP-lowering product would need evidence about that product rather than a reference to this association alone.
Study co-author Barbara Bendlin cautioned against simple instructions to stop eating particular foods. Histidine is needed by the body and is widespread in food. The researchers did not identify a food or eating pattern that reliably lowers ImP.
Knowing that bacteria use a nutrient to make a molecule does not establish a useful food rule. The practical question is whether a dietary change produces a helpful outcome in people. This study did not supply that answer.
For a broader nutrition context, FitBrainLab's comparison of eating patterns studied for brain health addresses a separate body of evidence. Keeping these questions separate prevents a finding about one bacterial molecule from becoming a claim about an entire diet.
The finding gives researchers a specific relationship to investigate. For doctors and patients, it offers context for understanding a new research report rather than a treatment plan.
Questions about personal memory changes or major changes to diet belong in a discussion with a qualified health professional. Readers can bring the report to that conversation without treating its headline as an instruction. The clearest practical distinction is between learning about a possible biological pathway and acting on a tested intervention.
The human analysis was observational. It found that blood ImP levels and cognitive outcomes were associated. It did not establish that ImP caused the decline.
This is the main boundary around the human finding. Seeing two measurements move together does not by itself show that changing one will change the other. The unanswered question is whether reducing ImP in people would improve cognitive outcomes or alter Alzheimer’s-related biology.
That question matters more for personal decisions than the association alone. A molecule can be scientifically interesting without yet being a useful target for prevention or treatment. The reported human findings support further investigation of ImP, not a promise that controlling it will preserve memory.
The reported links with Alzheimer’s-related markers should not be read as diagnoses. Medical Daily described these as research markers, including pTau-217. A connection between ImP and a marker is not the same as a clinical determination that a person has Alzheimer’s disease.
Cognitive-test scores and blood markers also provide different kinds of information. Their appearance in the same study makes the research question more detailed. It does not turn the report into a way for readers to interpret their own symptoms or predict their future.
The mouse and laboratory findings offer possible biological explanations to investigate. They do not establish that the same effects occur in people. Experimental evidence from those settings cannot settle the human cause-and-effect question.
The distinction is especially relevant when a paper's title sounds more direct than its human findings. The title refers to the combined research. A reader interested in personal health still needs to ask which conclusions came from people and which came from experiments.
FitBrainLab's discussion of other gut-and-brain research provides another opportunity to practice that distinction. Useful questions include what was measured and whether the research tested an intervention. These questions keep attention on the evidence rather than the appeal of a microbiome explanation.
The study makes the gut-brain research question more specific. Rather than referring broadly to gut bacteria, it identifies a molecule linked with cognitive testing and Alzheimer’s-related blood measurements. That gives future research a clearer relationship to examine.
Its long-term value will rest on what researchers learn next about changing ImP in people. The key issue is whether that change affects outcomes that matter for cognitive health. The current finding helps define that question.
For adults interested in maintaining memory and independence, this is a development worth understanding without turning it into a new daily rule. A careful reading preserves both the scientific interest and the practical perspective: a clearer research target is meaningful progress, but it is not yet a demonstrated way to protect memory.
Turning an ImP association into a food rule skips the evidence; FitBrainLab separates research findings from claims about daily habits. Uncertainty about nutrition and cognitive health is the practical issue here, and its research-led guidance helps adults 60+ understand brain-aging evidence without hype or promises about memory.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
